COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...

the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group. Ascendis Pharma NewsMORE Related Stocks ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

- Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to use approximately $25 million to ...

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $200.00 to $225.00 in a research note issued to investors on Thursday,Benzinga reports.

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports.